SK283003B6 - 1-beta-D-Arabinofuranozylcytozínový derivát, jeho použitie a farmaceutický prípravok s jeho obsahom - Google Patents

1-beta-D-Arabinofuranozylcytozínový derivát, jeho použitie a farmaceutický prípravok s jeho obsahom Download PDF

Info

Publication number
SK283003B6
SK283003B6 SK80-98A SK8098A SK283003B6 SK 283003 B6 SK283003 B6 SK 283003B6 SK 8098 A SK8098 A SK 8098A SK 283003 B6 SK283003 B6 SK 283003B6
Authority
SK
Slovakia
Prior art keywords
ara
elaidate
hydrogen
treatment
cells
Prior art date
Application number
SK80-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK8098A3 (en
Inventor
Finn Myhren
Bernt Borretzen
Are Dalen
Kjell Torgeir Stokke
Original Assignee
Conpharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conpharma As filed Critical Conpharma As
Publication of SK8098A3 publication Critical patent/SK8098A3/sk
Publication of SK283003B6 publication Critical patent/SK283003B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyamides (AREA)
  • Artificial Filaments (AREA)
SK80-98A 1995-07-25 1996-07-12 1-beta-D-Arabinofuranozylcytozínový derivát, jeho použitie a farmaceutický prípravok s jeho obsahom SK283003B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515279.9A GB9515279D0 (en) 1995-07-25 1995-07-25 Improved therapeutic agents
PCT/NO1996/000179 WO1997005154A1 (en) 1995-07-25 1996-07-12 Improved therapeutic agents

Publications (2)

Publication Number Publication Date
SK8098A3 SK8098A3 (en) 1998-07-08
SK283003B6 true SK283003B6 (sk) 2003-01-09

Family

ID=10778247

Family Applications (1)

Application Number Title Priority Date Filing Date
SK80-98A SK283003B6 (sk) 1995-07-25 1996-07-12 1-beta-D-Arabinofuranozylcytozínový derivát, jeho použitie a farmaceutický prípravok s jeho obsahom

Country Status (25)

Country Link
US (2) US6316425B1 (es)
EP (1) EP0842185B1 (es)
JP (2) JP4372227B2 (es)
KR (1) KR100401909B1 (es)
AT (1) ATE207076T1 (es)
AU (1) AU714814B2 (es)
CA (1) CA2227533C (es)
CZ (1) CZ291612B6 (es)
DE (1) DE69616074T2 (es)
DK (1) DK0842185T3 (es)
ES (1) ES2166900T3 (es)
GB (1) GB9515279D0 (es)
HU (1) HU224839B1 (es)
IL (2) IL122942A0 (es)
MX (1) MX9800622A (es)
NO (1) NO313985B1 (es)
NZ (1) NZ313790A (es)
PL (1) PL183601B1 (es)
PT (1) PT842185E (es)
RU (1) RU2165260C2 (es)
SK (1) SK283003B6 (es)
TW (1) TW434251B (es)
UA (1) UA55389C2 (es)
WO (1) WO1997005154A1 (es)
ZA (1) ZA966047B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
CA2271135A1 (en) * 1996-11-12 1998-05-22 Medivir Ab Nucleosides
AU720451B2 (en) * 1997-01-24 2000-06-01 Conpharma As Gemcitabine derivatives
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20070160554A1 (en) * 2003-11-03 2007-07-12 Cognis Ip Management Gmbh Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
AU2008304380A1 (en) * 2007-09-26 2009-04-02 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
WO2011062503A1 (en) * 2009-11-20 2011-05-26 Clavis Pharma As Parenteral formulations of gemcitabine derivatives
JP5903097B2 (ja) * 2010-07-13 2016-04-13 クラビス ファーマ エイエスエイ エラシタラビン誘導体の非経口製剤
AU2013241341B2 (en) * 2012-03-28 2016-09-08 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
US20210052619A1 (en) 2018-01-15 2021-02-25 Yinuoke Medicine Science And Technology Company Ltd. Treatments for cachexia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894000A (en) * 1971-01-27 1975-07-08 Upjohn Co Ara-cytidine derivatives and process of preparation
FI105556B (fi) 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5641758A (en) 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof

Also Published As

Publication number Publication date
CA2227533A1 (en) 1997-02-13
NZ313790A (en) 1999-07-29
CZ16398A3 (cs) 1998-06-17
DK0842185T3 (da) 2002-02-04
US6316425B1 (en) 2001-11-13
ES2166900T3 (es) 2002-05-01
SK8098A3 (en) 1998-07-08
TW434251B (en) 2001-05-16
HUP9900924A3 (en) 2001-06-28
ZA966047B (en) 1997-02-04
IL122942A0 (en) 1999-05-09
ATE207076T1 (de) 2001-11-15
NO980296D0 (no) 1998-01-23
KR100401909B1 (ko) 2004-02-14
KR19990035804A (ko) 1999-05-25
MX9800622A (es) 1998-11-30
GB9515279D0 (en) 1995-09-20
UA55389C2 (uk) 2003-04-15
PL324690A1 (en) 1998-06-08
HU224839B1 (en) 2006-03-28
JP4372227B2 (ja) 2009-11-25
JP2009215326A (ja) 2009-09-24
EP0842185B1 (en) 2001-10-17
IL122942A (en) 2006-12-10
US6335322B1 (en) 2002-01-01
AU6633596A (en) 1997-02-26
RU2165260C2 (ru) 2001-04-20
EP0842185A1 (en) 1998-05-20
CZ291612B6 (cs) 2003-04-16
AU714814B2 (en) 2000-01-13
JP2002504068A (ja) 2002-02-05
JP5087052B2 (ja) 2012-11-28
CA2227533C (en) 2007-01-09
NO313985B1 (no) 2003-01-13
HUP9900924A2 (hu) 2001-05-28
WO1997005154A1 (en) 1997-02-13
NO980296L (no) 1998-01-23
PL183601B1 (pl) 2002-06-28
DE69616074T2 (de) 2002-06-06
DE69616074D1 (de) 2001-11-22
PT842185E (pt) 2002-04-29

Similar Documents

Publication Publication Date Title
JP5087052B2 (ja) 改良された治療剤
KR100483256B1 (ko) 젬시타빈 유도체
CA2140653A1 (en) Protein kinase inhibitors and related compounds combined with taxol
US4239905A (en) 1-β-D-Arabinofuranosylcytosine-5'-oleyl phosphate and salts thereof
DK166830B1 (da) 5-fluor-2'-deoxyuridin-3',5'-derivater, hydrater og salte heraf, fremgangsmaade til fremstilling af disse samt antitumorpraeparater indeholdende disse derivater
KR100832167B1 (ko) 방사선치료 증감제
RU2194711C2 (ru) Производные гемцитабина
KR20220039748A (ko) 암 치료용 디뉴클레오티드 화합물 및 그의 의약 용도
CN111285900B (zh) 基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途
MXPA99006790A (es) Derivados de gemcitabina
NO318934B1 (no) Gemcitabinderivater

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130712